Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Olverembatinib

Pulmonary embolism

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wen Z, et al. Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study. Blood 142 (Suppl. 1): 4538, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-181850 [abstract] Wen Z, et al. Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study. Blood 142 (Suppl. 1): 4538, Nov 2023. Available from: URL: https://​dx.​doi.​org/​10.​1182/​blood-2023-181850 [abstract]
Metadaten
Titel
Olverembatinib
Pulmonary embolism
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54232-7

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Obinutuzumab

Case report

Corticosteroids

Case report

Theophylline

Case report

Daptomycin